Bruker Corporation (BRKR)
US — Healthcare Sector
Automate Your Wheel Strategy on BRKR
With Tiblio's Option Bot, you can configure your own wheel strategy including BRKR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BRKR
- Rev/Share 22.7098
- Book/Share 12.314
- PB 2.7162
- Debt/Equity 1.3385
- CurrentRatio 1.6051
- ROIC 0.0203
- MktCap 4945808157.0
- FreeCF/Share 0.3252
- PFCF 100.3207
- PE 62.0844
- Debt/Assets 0.3841
- DivYield 0.0061
- ROE 0.044
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BRKR | Citigroup | Buy | Neutral | -- | $40 | May 22, 2025 |
| Initiation | BRKR | Guggenheim | -- | Buy | -- | $72 | Dec. 19, 2024 |
| Initiation | BRKR | UBS | -- | Neutral | -- | $66 | Dec. 10, 2024 |
| Upgrade | BRKR | Goldman | Sell | Neutral | -- | $60 | Dec. 5, 2024 |
| Initiation | BRKR | Barclays | -- | Overweight | -- | $75 | Oct. 15, 2024 |
| Downgrade | BRKR | Wolfe Research | Outperform | Peer Perform | -- | -- | Sept. 30, 2024 |
| Initiation | BRKR | Wells Fargo | -- | Overweight | -- | $78 | Aug. 28, 2024 |
News
Bruker (BRKR) Reports Q4 Earnings: What Key Metrics Have to Say
BRKR
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Bruker (BRKR) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
About Bruker Corporation (BRKR)
- IPO Date 2000-08-04
- Website https://www.bruker.com
- Industry Medical - Devices
- CEO Frank H. Laukien
- Employees 11396
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.